Dissecting the role of eosinophil cationic protein in upper airway disease

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 1, 2012, Pages 18-23

  Bystrom, Jonas ^a   Patel, Smita Y ^b   Amin, Kawa ^c,d   Bishop Bailey, David ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF SULAIMANI   (Iraq)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Entopy; Eosinophil cationic protein; IL 17; IL 33; Mepolizumab

Indexed keywords

BENRALIZUMAB; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL GRANULE PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 33; MEPOLIZUMAB; MITOCHONDRIAL DNA; OMALIZUMAB; RIBONUCLEASE; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC REACTION; ASTHMA; ATOPIC KERATOCONJUNCTIVITIS; CYTOTOXICITY; DEGRANULATION; EOSINOPHILIA; HUMAN; NOSE MUCOSA; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINOSINUSITIS; UPPER RESPIRATORY TRACT; UPPER RESPIRATORY TRACT INFECTION;

EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; HUMANS; INTERLEUKIN-17; INTERLEUKINS; RHINITIS; SINUSITIS;

EID: 84857044627     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834eccaf     Document Type: Review

References (47)

1. Amin K, Rinne J, Haahtela T, et al. Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. J Allergy Clin Immunol 2001; 107:249-257. (Pubitemid 32173901)
2. Bystrom J, Amin K, Bishop-Bailey D. Analysing the eosinophil cationic protein: a clue to the function of the eosinophil granulocyte. Respir Res 2011; 12:10. This review details experiments performed to assess function of ECP. Furthermore, biological levels of ECP in various diseases are summarized.
3. Roufosse F, de Lavareille A, Schandene L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:828-835; e823.
4. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008; 38:709-750. (Pubitemid 351550670)
5. Chu VT, Frohlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011; 12:151-159. In this study, eosinophils have been localized to the murine bone marrow, wherein they support antibody production from plasma cells.
6. Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011; 332:243-247. Murine eosinophils are found in adipose tissue, adjacent to macrophages supporting their anti-inflammatory phenotype.
7. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
8. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
9. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
10. Pavord ID, Bush A. Antiige for asthma in inner-city children. N Engl J Med 2011; 364:2556-2557; author reply 2557-2558.
11. Broekema M, Volbeda F, Timens W, et al. Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of fev(1). Respir Med 2010; 104:1254-1262.
12. Kolbeck R, Kozhich A, Koike M, et al. Medi-563, a humanized antiil-5 receptor alpha mab with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125:1344-1353; e1342.
13. Venge P, Bystrom J, Carlson M, et al. Eosinophil cationic protein (ecp): molecular and biological properties and the use of ecp as a marker of eosinophil activation in disease. Clin Exp Allergy 1999; 29:1172-1186. (Pubitemid 29406464)
14. Peona V, De Amici M, Quaglini S, et al. Serum eosinophilic cationic protein: is there a role in respiratory disorders? J Asthma 2010; 47:131-134.
15. Koh GC, Shek LP, Goh DY, et al. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med 2007; 101:696-705. (Pubitemid 46335585)
16. Burch JB, Svendsen E, Siegel PD, et al. Endotoxin exposure and inflammation markers among agricultural workers in colorado and nebraska. J Toxicol Environ Health A 2010; 73:5-22.
17. Wu KG, Li TH, Chen CJ, et al. Correlations of serum interleukin-16, total ige, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis. Int J Immunopathol Pharmacol 2011; 24: 15-23.
18. Kim ST, Han DH, Moon IJ, et al. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy 2010; 24:271-275.
19. Neves JS, Radke AL, Weller PF. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol 2010; 125:477-482. In this study, the authors have located the cysteinyl and purinergic receptors cysLT1R, cysLT2R and P2Y12R on released granules mediating degranulation upon stimulation.
20. Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 2008; 14:949-953.
21. Simon D, Hoesli S, Roth N, et al. Eosinophil extracellular DNA traps in skin diseases. J Allergy Clin Immunol 2011; 127:194-199. Eosinophil mitochondrial DNA coated with granule proteins is found released in various eosinophil-engaging skin diseases.
22. Dworski R, Simon HU, Hoskins A, et al. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol 2011; 127:1260-1266. Eosinophil mitochondrial DNA coated with granule proteins is found released in allergic asthmatic patients' airways.
23. Castano R, Maghni K, Castellanos L, et al. Proinflammatory mediators in nasal lavage of subjects with occupational rhinitis. Otolaryngol Head Neck Surg 2010; 143:301-303; e301.
24. Rondon C, Canto G, Blanca M. Local allergic rhinitis: a new entity, characterization and further studies. Curr Opin Allergy Clin Immunol 2010; 10:1-7.
25. Liu F, Zhang J, Liu Y, et al. Inflammatory profiles in nasal mucosa of patients with persistent vs intermittent allergic rhinitis. Allergy 2010; 65:1149-1157.
26. Ahn Y, An SY, Won TB, et al. Nasal polyps: an independent risk factor for bronchial hyperresponsiveness in patients with allergic rhinitis. Am J Rhinol Allergy 2010; 24:359-363.
27. Kampe M, Lampinen M, Stolt I, et al. Pi3-kinase regulates eosinophil and neutrophil degranulation in patients with allergic rhinitis and allergic asthma irrespective of allergen challenge model. Inflammation 2011. [Epub ahead of print]
28. Kampe M, Stolt I, Lampinen M, et al. Patients with allergic rhinitis and allergic asthma share the same pattern of eosinophil and neutrophil degranulation after allergen challenge. Clin Mol Allergy 2011; 9:3.
29. Forester JP, Calabria CW. Local production of ige in the respiratory mucosa an the concept of entopy: does allergy exist in nonallergic rhinitis? Ann Allergy Asthma Immunol 2010; 105:249-255.
30. Rondon C, Dona I, Lopez S, et al. Seasonal idiopathic rhinitis with local inflammatory response and specific ige in absence of systemic response. Allergy 2008; 63:1352-1358. In this study, ECP is detected in nasal washouts of patients with rhinitis and entopy, suggesting eosinophils contributing to the disease.
31. Bager P, Arnved J, Ronborg S, et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010; 125:123-130; e121-e123.
32. Matsuwaki Y, Wada K, Moriyama H, et al. Human eosinophil innate response to alternaria fungus through protease-activated receptor-2. Int Arch Allergy Immunol 2011; 155 (Suppl 1):123-128.
33. Ishitoya J, Sakuma Y, Tsukuda M. Eosinophilic chronic rhinosinusitis in Japan. Allergol Int 2010; 59:239-245.
34. De Corso E, Baroni S, Romitelli F, et al. Nasal lavage ccl24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation. Rhinology 2011; 49:174-179.
35. Gu Z, Cao Z, Jin M. Expression and role of acidic mammalian chitinase and eotaxin-3 in chronic rhinosinusitis with nasal polyps. J Otolaryngol Head Neck Surg 2011; 40:64-69.
36. Plager DA, Kahl JC, Asmann YW, et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PLoS One 2010; 5:e11450.
37. BergerG, Kogan T, Paker M, et al. Pediatric chronic rhinosinusitis histopathology: differences and similarities with the adult form. Otolaryngol Head Neck Surg 2011; 144:85-90.
38. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107-1119.
39. Makihara S, Okano M, Fujiwara T, et al. Regulation and characterization of IL-17a expression in patients with chronic rhinosinusitis and its relationship with eosinophilic inflammation. J Allergy Clin Immunol 2010; 126:397-400. This work proposes SEB in CRS nasal polyps activating eosinophils and extending their life. Eosinophils (and macrophages) were found to respond to SEB with IL-17 production, which induced GM-CSF production by other cells. GM-CSF is known to prolong life of eosinophils explaining their accumulation in polyps.
40. Saitoh T, Kusunoki T, Yao T, et al. Role of interleukin-17a in the eosinophil accumulation and mucosal remodeling in chronic rhinosinusitis with nasal polyps associated with asthma. Int Arch Allergy Immunol 2010; 151:8-16.
41. Li X, Meng J, Qiao X, et al. Expression of tgf, matrix metalloproteinases, and tissue inhibitors in chinese chronic rhinosinusitis. J Allergy Clin Immunol 2010; 125:1061-1068.
42. Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol 2010; 10:478-485.
43. Cherry WB, Yoon J, Bartemes KR, et al. A novel il-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008; 121: 1484-1490. (Pubitemid 351787349)
44. Chow JY, Wong CK, Cheung PF, et al. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010; 7:26-34. This study details intracellular signaling in eosinophils activated by IL-33, leading to survival and ICAM1 upregulation.
45. Kim HR, Jun CD, Lee YJ, et al. Levels of circulating il-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. J Allergy Clin Immunol 2010; 126:880-882; e886. Serum ECP is better than plasma IL-33 to discriminate eosinophilic disease.
46. Ohtomo K, Ebihara N, Matsuda A, et al. Role of tgf-beta in tissue eosinophilia associated with vernal keratoconjunctivitis. Exp Eye Res 2010; 91:748-754.
47. Sheahan P, Ahn CN, Harvey RJ, et al. Local ige production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg 2010; 39:45-51.